LncRNA DSCAM-AS1调节miR-150-5p/BRAF轴对甲状腺癌细胞恶性生物学行为的影响

doi:10.3969/j.issn.1006-5725.2023.23.004

摘要/Abstract

摘要：

目的探讨lncRNA DSCAM-AS1调节miR-150-5p/BRAF轴对甲状腺癌（TC）细胞恶性生物学行为的影响。方法 qRT-PCR检测TC细胞中DSCAM-AS1表达；FISH、pull down实验、双荧光素酶报告基因实验验证DSCAM-AS1、BRAF与miR-150-5p靶向调控关系；检测SW579细胞增殖、迁移和侵袭，Western blot检测BRAF、E-cadherin、vimentin蛋白表达；小鼠体内肿瘤形成实验验证DSCAM-AS1对TC肿瘤生长的影响。结果 DSCAM-AS1在TC细胞中高表达（P < 0.05）；DSCAM-AS1、BRAF与miR-150-5p存在靶向调控关系；抑制DSCAM-AS1表达或过表达miR-150-5p可显著抑制SW579细胞增殖、迁移、侵袭及EMT（P < 0.05）；抑制miR-150-5p表达或过表达BRAF可逆转抑制DSCAM-AS1表达或过表达miR-150-5p对SW579细胞恶性行为的抑制作用（P < 0.05）；体内实验显示，抑制DSCAM-AS1表达可显著抑制小鼠移植瘤的生长（P < 0.05）。结论 DSCAM-AS1在TC细胞中上调表达，抑制DSCAM-AS1表达可通过调节miR-150-5p/BRAF信号轴，抑制TC恶性进展。

关键词: lncRNA DSCAM-AS1, miR-150-5p/BRAF轴, 甲状腺癌, 增殖, 迁移, 侵袭

Abstract:

Objective To investigate the impact of lncRNA DSCAM-AS1 on the malignant biological behaviors of thyroid cancer （TC） cells by regulating the miR-150-5p/BRAF axis. Methods The expression of DSCAM-AS1 in TC cells was detected by qRT-PCR，and the best intervention cell line was screened.； the relationship between DSCAM-AS1， BRAF and miR-150-5p targeting regulation was verified by FISH， pull down and double Luciferase reporter gene experiment； The proliferation，migration and invasion of SW579 cells were detected； Western blot was applied to detect the expression of BRAF， E-Cadherin， and vimentin proteins； the tumor formation experiment in mice was applied to verify the effect of DSCAM-AS1 on TC tumor growth. Results DSCAM-AS1 was highly expressed in TC tissue and cells （P < 0.05）； There is a targeted regulation relationship between DSCAM-AS1，BRAF and miR-150-5p； inhibition of DSCAM-AS1 expression or overexpression of miR-150-5p obviously inhibited the proliferation， migration， invasion， and EMT of SW579 cells （P < 0.05）； Inhibition of miR-150-5p expression or overexpression of BRAF reversed the inhibitory effect of inhibition of DSCAM-AS1 expression or overexpression of miR-150-5p on the malignant behavior of SW579 cells （P < 0.05）； in vivo experiments showed that inhibiting the expression of DSCAM-AS1 obviously inhibited the growth of transplanted tumors in mice （P < 0.05）. Conclusion DSCAM-AS1 is up-regulated in TC cells， inhibiting the expression of LncRNA DSCAM-AS1 can inhibit the malignant progression of TC by regulating the miR-150-5p/BRAF signaling axis.

Key words: lncRNA DSCAM-AS1, miR-150-5p/BRAF axis, thyroid cancer, proliferation, migration, invasion

中图分类号:

R736.1

彭云,温美玲,吕云霞,陈万志,何春,俞建平,丁振罗. LncRNA DSCAM-AS1调节miR-150-5p/BRAF轴对甲状腺癌细胞恶性生物学行为的影响[J]. 实用医学杂志, 2023, 39(23): 3043-3050.

Yun PENG,Meiling WEN,Yunxia LV,Wanzhi CHEN,Chun HE,Jianping YU,Zhenluo. DING. Impact of LncRNA DSCAM⁃AS1 on the malignant biological behaviors of thyroid cancer cells by regulating the miR⁃150⁃5p/BRAF axis[J]. The Journal of Practical Medicine, 2023, 39(23): 3043-3050.

图/表 6

图1

图2

图3

图4

图5

图6

参考文献 24

1	ZHOU Y， LIU S， LUO Y，et al. IncRNA MAPKAPK5-AS1 promotes proliferation and migration of thyroid cancer cell lines by targeting miR-519e-5p/YWHAH［J］. Eur J Histochem，2020，64（4）：3177-3185.
2	HU J， YUAN I J， MIRSHAHIDI S，et al. Thyroid Carcinoma： Phenotypic Features，Underlying Biology and Potential Relevance for Targeting Therapy［J］. Int J Mol Sci，2021，22（4）：1950-1974.
3	WANG S， LUO J， ZHONG Z，et al. Treatment and prognosis for patients with differentiated thyroid carcinoma bone metastases［J］. Transl Cancer Res，2020，9（1）：972-982.
4	TAN Y T， LIN J F， Li T，et al. LncRNA-mediated posttranslational modifications and reprogramming of energy metabolism in cancer［J］. Cancer Commun （Lond），2021，41（2）：109-120.
5	WANG Z， LI S， ZHANG G. LncRNA DSCAM-AS1 Negatively Interacts with miR-124 to Promote Hepatocellular Carcinoma Proliferation［J］. Crit Rev Eukaryot Gene Expr，2022，32（3）：1-8.
6	LI L， CHEN P， HUANG B，et al. lncRNA DSCAM-AS1 facilitates the progression of endometrial cancer via miR-136-5p［J］. Oncol Lett，2021，22（6）：825-833.
7	YU C L， XU N W， JIANG W，et al. LncRNA DSCAM-AS1 promoted cell proliferation and invasion in osteosarcoma by sponging miR-101［J］. Eur Rev Med Pharmacol Sci， 2020，24（14）：7709-7717.
8	GUO K， QIAN K， SHI Y，et al. LncRNA-MIAT promotes thyroid cancer progression and function as ceRNA to target EZH2 by sponging miR-150-5p［J］. Cell Death Dis， 2021，12（12）：1097-1108.
9	WEI X， WANG X， XIONG J，et al. Risk and Prognostic Factors for BRAFV600E Mutations in Papillary Thyroid Carcinoma. Biomed Res Int［J］. 2022，2022（1）：1-13.
10	GUO F， FU Q， WANG Y，et al. Long non-coding RNA NR2F1-AS1 promoted proliferation and migration yet suppressed apoptosis of thyroid cancer cells through regulating miRNA-338-3p/CCND1 axis［J］. J Cell Mol Med，2019，23（9）：5907-5919.
11	余江涛，王世杰，张高飞，等. 血清甲状腺球蛋白、促甲状腺激素联合检测对行甲状腺全切术后未接受清甲治疗的分化型甲状腺癌患者复发的预测价值［J］. 实用医学杂志，2023，39（9）：1159-1163.
12	SHI L， CONG Y Z， WANG Z J. LncRNA NORAD promotes thyroid carcinoma progression by targeting miR-451［J］. Eur Rev Med Pharmacol Sci， 2021，25（20）：6187-6195.
13	LIU H， DENG H， ZHAO Y，et al. LncRNA XIST/miR-34a axis modulates the cell proliferation and tumor growth of thyroid cancer through MET-PI3K-AKT signaling［J］. J Exp Clin Cancer Res， 2018，37（1）：279-290.
14	LU C， XIE T， GUO X，et al. LncRNA DSCAM-AS1 Promotes Colon Cancer Cells Proliferation and Migration via Regulating the miR-204/SOX4 Axis［J］. Cancer Manag Res， 2020，12（1）：4347-4356.
15	SHETTY A， VENKKANESH T， KABBEKOUDU S P，et al. LncRNA-miRNA-mRNA regulatory axes in endometrial cancer： a comprehensive overview［J］. Arch Gynecol Obstet， 2022，306（5）：1431-1447.
16	CHEN X， XU X， PAN B，et al. miR-150-5p suppresses tumor progression by targeting VEGFA in colorectal cancer［J］. Aging （Albany NY）， 2018，10（11）：3421-3437.
17	DAI F Q， LI C R， FAN X Q，et al. miR-150-5p Inhibits Non-Small-Cell Lung Cancer Metastasis and Recurrence by Targeting HMGA2 and β-Catenin Signaling［J］. Mol Ther Nucleic Acids，2019，16（1）：675-685.
18	李文强，刘慧颖，任卫东. 干扰Hsa_circ_0023642调控miR-653对甲状腺癌细胞生物行为的影响［J］. 实用医学杂志， 2021，37（21）：2727-2732.
19	李秀君，刘宝利，朱翠敏. lncRNA TUG1通过miR-524-5p/BRAF轴调节甲状腺乳头状癌TPC-1细胞的增殖、凋亡和EMT进程［J］. 中国肿瘤生物治疗杂志， 2022，29（5）：434-441.
20	MAZIERES J， CROPET C， MONTANE L，et al. Vemurafenib in non-small-cell lung cancer patients with BRAFV600 and BRAFnonV600 mutations［J］. Ann Oncol， 2020，31（2）：289-294.
21	MORRIS V K， BEKAII-SABB T. Improvements in Clinical Outcomes for BRAFV600E-Mutant Metastatic Colorectal Cancer［J］. Clin Cancer Res， 2020，26（17）：4435-4441.
22	CHUNG J H. BRAF and TERT promoter mutations： clinical application in thyroid cancer［J］. Endocr J， 2020，67（6）：577-584.
23	SUBBIASH V， BAIK C， KIRKWOOD J M. Clinical Development of BRAF plus MEK Inhibitor Combinations［J］. Trends Cancer，2020，6（9）：797-810.
24	CUCCURULLO V， STASIO G D， CASCINI G L. PET/CT in thyroid cancer - the importance of BRAF mutations［J］. Nucl Med Rev Cent East Eur， 2020，23（2）：97-102.

[1]	刘景,冷春涛,王艳. circRNA SIPA1L1修饰牙髓干细胞来源外泌体促血管生成能力的机制[J]. 实用医学杂志, 2024, 40(9): 1211-1217.
[2]	李文昕,卢敏君,林莉,刘月琴,朱小兰. circRAF1调节人卵巢颗粒细胞的增殖与凋亡[J]. 实用医学杂志, 2024, 40(7): 910-917.
[3]	杨贞,江少如,陈小燕,陈晓琳,邓伟民,郭新宇. 经后增殖方对控制性超促排卵大鼠卵巢GDF9分泌及颗粒细胞凋亡的影响[J]. 实用医学杂志, 2024, 40(7): 918-923.
[4]	赵敏,倪平,翟惠莹,靳小可,杨玉琼. 淋巴样增强结合因子1在B细胞慢性淋巴增殖性疾病中的表达[J]. 实用医学杂志, 2024, 40(7): 984-988.
[5]	高丽娜,刘小晖,张玉芳,刘小玲,何晓春,高晶,张莉,孙俊,王秀娟,董燕. LncRNA SNHG8在胎盘植入的表达及其对滋养细胞侵袭及迁移的影响[J]. 实用医学杂志, 2024, 40(5): 646-652.
[6]	徐俐,胡珊珊,赵海明. LncRNA GNAS-AS1通过调节miR-449a/Notch1轴参与胃癌细胞的增殖和迁移[J]. 实用医学杂志, 2024, 40(4): 483-489.
[7]	王敬才,郭春艳,杨丽昕,敬小青. 血清RAGE、HMGB1水平与重症肺炎急性呼吸窘迫综合征发病及IFN⁃γ/IL⁃4变化的关系[J]. 实用医学杂志, 2024, 40(4): 515-520.
[8]	马润伟,穆纯杰,桂雯婷,邓瑶,赵敏章,柳民,宋怡. LncRNA SENCR靶向miR⁃206调控人主动脉夹层血管平滑肌细胞增殖和凋亡[J]. 实用医学杂志, 2024, 40(3): 302-308.
[9]	吴冰儿,李清,杨可容,张健,余逸,雷蕾,胡博. 亚精胺对弥漫大B细胞淋巴瘤细胞株增殖和凋亡的影响[J]. 实用医学杂志, 2024, 40(22): 3130-3137.
[10]	罗青,黄金金,任婷婷,周瑞华,徐栋花,王振华,王国颖. 人脐带干细胞外泌体对人毛乳头细胞增殖的影响[J]. 实用医学杂志, 2024, 40(20): 2828-2834.
[11]	王敏,母丹,孔德军,杨莉,叶璐,贺丹. HPV16 E6调控miR-23a表达促进宫颈癌细胞侵袭、迁移[J]. 实用医学杂志, 2024, 40(2): 146-152.
[12]	何志捷,李伟超,何铭辉,陈晓彤,林钊,植耀炜. 微滴式数字PCR技术快速诊断侵袭性念珠菌病的方法建立[J]. 实用医学杂志, 2024, 40(19): 2738-2746.
[13]	朱枫,李青,陈曦,贺洋,彭蕾. 细针穿刺活检联合高通量测序技术在甲状腺结节诊疗中的应用[J]. 实用医学杂志, 2024, 40(17): 2471-2476.
[14]	王发辉,邓青春,林佳佳,陈春妃. GATA3介导miR-21/PTEN轴对子宫内膜癌细胞增殖、侵袭的影响[J]. 实用医学杂志, 2024, 40(15): 2069-2074.
[15]	肖无双,洪林杰,余针,杨萍,张杰铭,彭思扬,魏向阳,陈奕东,刘思德,王继德. S100A7A在胃癌中的表达及对增殖转移的影响[J]. 实用医学杂志, 2024, 40(10): 1344-1350.